Member Info for larry10

https://www.linkedin.com/posts/dr-thomas-heister-66222925_novacyt-winterplexpcrassay-versalab-activity-7005859736545820672-Dy2J?utm_source=share&utm_medium=member_android

On trial at NHS or is it just that the vita pcr had been approved on CTDA in November 2022 ? Or are you speaking about another test kit ?

Exmex, like you i follow morningstar, but also wsj, which is not Bad either.

JO hambro finished selling in November.
And i think Octopus is at least partialy out also in November/december.

Hi sur Digby, i Saw those numbers too and though the same thing... 7 products... Coïncidence or not i dunno but thought about ncyt Reading that part.

I did not told gov Was going to pay up tomorrow.
But of course i do wish that this matter Was closed, and with a good outcome for ncyt. Not even sure you Want that p100.

"There is strong evidence that the principal objective of CTDA (Objective 1) has been met, namely to improve the quality of tests available on the private market by setting minimum performance thresholds and reducing the incidence of false positive and negative results.

The number of applications and successful and unsuccessful outcomes demonstrate a consistent supply of tests coming through the approval process and would indicate that, despite some difficulties, companies with suitably robust procedures and evidence are able to successfully satisfy the requirements of CTDA and get their tests onto the UK market.

While the approved register does not allow consumers to compare tests (Objective 4) based on performance, it allows users to confidently select products that had met CTDA requirements and were able to meet defined minimum performance thresholds, improving consumer information and filtering out poor products (Objective 2)."

But this is good to read this, as Exsig, just like genesig 3G are meeting those requirements and have been validated on CTDA.
It does prove that those tests are working well.

So DHSCs claim looking like they have some lead in the wing. Just like privateeye story.

Interesting view 21ats.

P100, did i create this website ?
https://www.eurofins.com/contact-us/worldwide-interactive-map/united-kingdom/eurofins-microgen/

Eurofins Microgen
Unit 1, Watchmoor Point
Camberley
GU15 3AD
Surrey
United Kindom

info@microgenbioproducts.com

microgenbioproducts.com

Something is weird no ?
Same adress, same name, sending on ncyts website, etc...

More than that i dont know.

Neilrich, eurofins has tons of subsidiaries with différents names. So that doesnt choc me.
But makes no sense that ncyt didnt clearly told us they sold microgen. And for how much. And what assays and assets ofnlicrogen did they kept or sold etc

Gizmo, the mpx test is from primerdesign, so i dont get what you mean ?

It's nice but it has nothing to do with microgen. Other "COVID stocks" like biosynex are also up. More likely news about china etc
It will be hard to maintain this rise in the time without concrete things imho.

If anyone Can make sense of it

https://twitter.com/Larry64450205/status/1608133427638816771?t=hjPTFrgVzbjEcfXBNxLOyQ&s=19

And of course those ones Never got any problem to get paid :

Innova Medical landed Covid contracts valued at £4 billion via the ‘VIP’ lane after its UK partner, a company trading under the name ‘Tried & Tested’ contacted Boris Johnson’s former advisor, Dominic Cummings.
Surescreen Diagnostics landed a £500m contract after Liam Fox MP referred the firm to Matt Han**** – Surescreen subsequently donated £20,000 to Liam Fox.
Matt Han**** assisted Ecolog International onto the ‘VIP’ lane after being contacted by Genix Healthcare – a company that has donated £156,000 to the Conservative Party. Han****’s Department paid Ecolog £38m in 2021, after the Government decided not to proceed with previously contracted Covid work.

https://www.gov.uk/government/publications/covid-19-testing-procurement/covid-19-testing-procurement

Primer design as a "Existing DHSC supplier". No lord or whatever like some others...

The "funny" part :

"Evaluating offers

All offers were evaluated by commercial professionals against the same criteria, assessing value for money and their ability to meet the government’s rigorous standards and deliver the service required. The COVID-19 testing services provided by suppliers were often for complex or innovative scientific products or services so where necessary, an expert technical evaluation process was also carried out."

So Exsig was good enough to get a contract ,no ... ?

I put that here again, thks to B2. It's not that old :

Transcript of YouTube Novacyt AGM Recording, august 2022, Question and Answer session only:

"Q3 The next question is about our current cash position (around £100 million) and whether we would buy-back shares or how we would utilise that cash.

James McCarthy answered

I think share buy back isn't ruled out, we also haven't declared the dividend for this year and in our annual accounts I think we should look at that in the wider capital structure of the company. We feel that the balance sheet gives us an opportunity to invest in the right areas of the business, we are being cautious about that. I think we'd like to make the right choices. We still feel we can create shareholder value by investing those funds, I think clearly if we got to a point that we felt that we could no longer do that we would look at the most economic way to return that cash to shareholders so that would be a dividend, or a capital reduction or share buyback that is something we would look at in the overall capital structure."

G. Raimondo, ncyts CCO, is gone. Started a New position at siemens again Yesterday.

See LinkedIn for his post.

https://novacyt.com/product/pathflow-strep-a/

Ressources > sales sheet

Performance vs. Culture
Sensitivity: 95.1%
Specificity: 97.8%
Accuracy: 97.1%

https://twitter.com/Larry64450205/status/1600462347427930112?t=fvWVCRfwSTz4EdJ1UfltJw&s=19

Again from their website, the different components btw easy/advanced/standard kits.

The main differences between an Genesig Easy and Genesig Advanced kit come down to 4 things:

Open or closed system
The Genesig Easy kits are a closed system kit where they have been tested, verified and are sold for the use on the Q16 and soon to be Q32 systems (in the next system update) only. Whereas the Genesig Advanced kits are open system Kits and therefore are designed to work with most qPCR machines.
Types of controls
The Genesig Easy kit contains a positive control and an internal extraction control, these both function to tell us what is going on with the chemistry in the kit to make sure results are reliable and trustworthy. The Genesig Advanced kits also offer both of these controls but also have an endogenous control which functions as a second test. By adding the endogenous control, it allows you to confirm all steps of your qPCR assay are working satisfactorily, from the extraction to the result.
Simplicity
The Genesig Easy kit is a simplified qPCR process with minimal pipetting mix and transfer steps. This greatly reduces risk of contamination and errors during the experiment set up by having a smaller interaction with samples and master mixes. The Genesig Advanced kit on the other hand has no master mix supplied as standard, this allows for the end user to select the relevant master mix for their experiment. This kit also comes without the reaction tubes allowing for end users to use plastic that fits their machine. Also, with the target primer/probe mix and internal extraction control primer/probe mix being separate, it allows the end user a greater experimental design choice. The Genesig Easy kit is a hold your hand walk through PCR whereas the Genesig Advanced gives the end user greater control of their experiment, both have different advantages depending on the end user.
Kit size
The final difference is the Genesig Easy kit comes with 50 reactions whereas the Genesig Advanced is supplied with enough master mix for 100-150 reactions

From their website.

Genesig COVID 3g added on CTDA list :
https://twitter.com/Larry64450205/status/1599774644256485376?t=HWoM1jZX_KZb23aXcJtSrQ&s=19

A LinkedIn post from amazon staff about the Mygo mini :
https://twitter.com/Larry64450205/status/1599788765098045441?t=9SYp7tg2GFsYmYFeYiH7tQ&s=19

Novacyt, whose Primerdesign subsidiary is based near Southampton, has rejected the claim and in June launched an £81.5 million counterclaim against the department for goods and services and damages for breach of contract.
Neale Hanvey, the Alba Party MP for Kirkcaldy and Cowdenbeath who worked in the NHS for 25 years before entering parliament, said the government had “damaged” confidence in Britain’s diagnostics industry and people’s livelihoods. “They completely over-promised,” he said.
Speaking in the Commons in January, Hanvey had said the government’s slogans of “build back better”, “level up” and “take back control” sounded hollow to the domestic diagnostics industry, “which has been utterly abandoned and betrayed by the government”.
He warned that building the industry was important to protect against future emergencies. “Covid is not the only novel virus that we could have to deal with, particularly as a result of global warming. Novel viruses and variants of ebola and dengue fever are possible, and it is therefore important for us to have testing and diagnostic equipment that is sensitive to all those different eventualities.”
One industry source, speaking confidentially, said there had been “two wasted years” for a “strategically important sector”. They added: “We as a country could have been in such a better position now if the government had followed up on the rhetoric.”
The source said that given the government’s hardening stance on Beijing, “where does that leave us when we need supplies from China” during the next crisis.
“It feels as though they are trying to highlight they are being tough in terms of value for money for the UK taxpayer, whereas what they are really doing is going after small UK companies and causing huge amounts of issues.”
Another industry source said: “If there was a call to arms again you can imagine what the response would be. It would be no thank you.”
Doris-Ann Williams, chief executive of the British In Vitro Diagnostics Association, which represents more than 200 companies, said she was “very aggrieved for those companies and their shareholders”. Investor confidence had been shaken, but the industry “as a whole” had not been harmed.
A spokeswoman for the Department of Health said: “From the very beginning of this pandemic we have worked with UK manufacturers to support the resilience of UK diagnostics. British innovation was at the forefront of our response to this pandemic and our partnerships with British firms were important in allowing the country to move to living with Covid.
“We have always been clear that government contracts must deliver value for taxpayer money and we will take action in instances where this does not happen.”

Omega has also been caught up in a separate legal dispute between the government and Abingdon Health, another Aim-quoted testing company, based in York. Omega was lined up to help manufacture a Covid antibody test on behalf of Abingdon at Alva as part of the government’s rapid test consortium, formed in April 2020, but Abingdon struggled to secure approval from the Medicines and Healthcare products Regulatory Agency for self-use testing.
The company reached a settlement with the department in June over delayed payments from the government for tests and services provided and has received £6.3 million. However, its balance sheet and prospects have been damaged by the dispute and it has led to the redundancy of 80 employees, more than half Abingdon’s workforce, at its sites in York and Doncaster.
Bosses at Abingdon spoke out last month — when it posted annual losses of £21.6 million, compared with a £7 million loss in 2021 — questioning the government’s ambitions to build a British diagnostics industry.

Abingdon had said the government’s “behaviours have been quite the opposite, both in terms of how they have dealt with established UK businesses and their preference to order significant quantities of tests, through recently established intermediaries, predominantly from Chinese companies”.
Abingdon, which was founded in 2008, had raised £22 million when it floated at 96p a share on Aim in December 2020, to help increase contract manufacturing of testing for Covid and other conditions. The shares, which peaked at more than 125p in January 2021, according to Refinitiv data, ended last week at 4½p, valuing the company at just £5.4 million.
The government is also locked in long-running High Court litigation with Novacyt, another Aim-quoted diagnostics company operating in Britain. The government launched a £135 million breach of contract claim against Novacyt, which has hit its shares and profits and forced it into a large writedown of stock. The government has alleged Novacyt’s test failed its validation tests and had “poor sensitivity and false negatives”.